Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. F.G.A. (Frank) Jansman

prof. dr. F.G.A. (Frank) Jansman

Bijzonder hoogleraar Klinische Farmacie, in het bijzonder in de oncologie

Publicaties

Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies: can alignment be improved?

Drug-drug interaction perpetrators of oxycodone in patients with cancer: frequency and clinical relevance

Afstellen en afstemmen van geneesmiddelen bij kanker

A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer

Effectiveness of a vitamin D regimen in deficient multiple myeloma patients and its effect on peripheral neuropathy

Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer

Assessing the binding interaction of polystyrene sulfonate with amitriptyline in healthy volunteers: a cross-over design — The BIND study

Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer

Differences in Evidentiary Requirements Between European Medicines Agency and European Health Technology Assessment of Oncology Drugs—Can Alignment Be Enhanced?

Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs: A practical and universal tool for management

Lees meer

Pers/media

Aandacht voor geneesmiddeleninteracties nog niet optimaal.